Bios Life combines clinical, laboratory, and genetic data to create ongoing "digital twin" models that continuously update an individual's cancer risk rather than relying on episodic scans. The company targets cancer survivors and people with higher genetic risk—groups it says together encompass over 40 million Americans—and highlights that more than 40% of people will get cancer in their lifetime with over 30% diagnosed at stage 3 or 4. Founded by former BioNTech executives and other clinicians and product leaders, the team includes ex-BioNTech and InstaDeep personnel leading strategy, AI, and operations. Bios Life owns commercial rights to the Nucleotide Transformer genomics foundation model developed by BioNTech-InstaDeep and has a multi-year data partnership with Tempus, with integration planned for Ambry Genetics. The company raised a $25 million seed round—their first external financing—and intends to use the resources to develop its technology and launch its U.S. platform in H2 2026, with a waitlist already open. Bios Life delivers care through a virtual clinic model with licensed teams working alongside cancer centers to provide continuous monitoring and tailored follow-up.

Total raised

$25M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2026